| Duramycin SPECT-CT: MILabs’ 2017 Image of the Year |
|
 |
| Representative Duramycin SPECT/CT image (left) shows early detection of tumor response. |
|
A team of researchers in the Molecular Imaging Center Antwerp (MICA), Belgium and Molecular Imaging Technologies Inc. (MTTI) of West Chester, PA, USA has received the award for “Image of the Year” in the 2017 MILabs Preclinical Image of the Year contest.
MTTI’s TumorVue tracer (Tc-99m-Duramycin) was to detect cancer treatment response as early as one day after a single administration of conatumumab. The objective was to compare responses of TumorVue SPECT to the gold standard FDG-PET. According to Prof. S. Strobants, Head of the Department of Nuclear Medicine of the University Hospital of Antwerp, TumorVue SPECT illustrates that one can effectively discriminate responders from non-responders. Read more |
|
|
Prof. F. Beekman receives SNMMI 2017 Hoffman Memorial Award
|
|
Frederik Beekman, PhD, CEO/CSO of MILabs B.V. and Professor at TU Delft, is the recipient of the SNMIMI 2017 Edward J. Hoffman Memorial Award. This award, given annually by the Computer and Instrumentation Council, recognizes individuals for their outstanding contributions to the field of medical imaging science.
Pictured from left to right are: Scott Metzler, Eric Frey, Frederik Beekman and James Galt |
|
|
|
Introduction of new VECTor5OI/CT enjoys overwhelming success
|
|
 |
| The new VECTor5OI/CT system: the game-changing fusion of molecular nuclear and optical imaging with true 4D UHR diagnostic CT. |
|
At the SNMMI 2017 conference in Denver, MILabs unveiled its new Series-5 PET, SPECT, OI, CT. While this new VECTor5OI/CT system looks similar to its predecessor, it features some significant performance improvements and multimodality enhancements, plus a game-changing 4D diagnostic UHR-CT.
On a single, scalable platform, the system offers hexamodal PET, SPECT, X-ray CT, bioluminescence, fluorescence and Cherenkov imaging. In addition, the system can now also handle ex vivo specimen with Exirad-3D SPECT at 150-micron resolution and CT imaging down to 2.5-micron voxel sizes. Better yet, for in vivo animal imaging, the system will deliver PET and SPECT images with unprecedented resolutions: 0.25 mm for SPECT and 0.6 mm for PET. However, one of the most innovative capabilities of the VECTor5OI/CT platform is the hardware and software fusion of molecular nuclear and optical imaging with true 4D diagnostic CT. Now think about the application possibilities this offers. Read more |
|
|
Customer in the spotlight: Dr. Ann-Marie Chacko, PhD of Duke-NUS in Singapore
|
|
| Dr. Ann-Marie Chacko heads the Duke-NUS Laboratory for Translational and Molecular Imaging (LTMI) and is an Assistant Professor in the Duke-NUS Programme in Cancer and Stem Cell Biology. Dr. Chacko’s research program is dedicated to the preclinical characterization of molecularly targeted systems as diagnostics and/or therapeutics for translational applications. Using advanced state-of-the-art multi-modal small animal imaging platforms, a major thrust of LTMI is to develop in vivo imaging approaches to non-invasively assess biologic, prognostic and therapeutic biomarkers for cancer, brain and immune function, and infectious diseases. Read the entire interview here. |
|
|
Meet us at upcoming conferences
- WMIC, September 13-16, 2017, Philadelphia, PA
- EANM, October 21-25, 2017, Vienna, Austria
- IEEE NSS/MIC, October 21-28, 2017 Atlanta, GA
- SFN, November 11-15, 2017, Washington, DC
- RSNA, November 26-December 1, 2017, Chicago, IL
|
|
|
|
